Amneal Pharmaceuticals (AMRX) operating margin

Operating margin · fiscal 2025
13.2%

Amneal Pharmaceuticals (AMRX) had an operating margin of 13.2% in fiscal 2025 (the year ended December 31, 2025). That is 0.7 percentage points higher than the 12.5% of fiscal 2024. Figures as of 18 Nov 2026, 01:05 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Operating margin, fiscal 2025
13.2%
Change on fiscal 2024
+0.7 pts
Highest on record
28.0%fiscal 2016
Lowest on record
-15.3%fiscal 2019
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Amneal Pharmaceuticals operating margin, in more detail

Across the 10 fiscal years on record (2016–2025), the highest was 28.0% in fiscal 2016 and the lowest -15.3% in fiscal 2019. The fiscal 2025 figure is higher than in 78% of the 9 earlier fiscal years on record, whose median is 8.5%.

Gross margin was 36.9% in fiscal 2025. Net margin was 2.4% in fiscal 2025.

History · 10 fiscal years

Operating margin by fiscal year

  • Operating margin
  • Gross margin
  • Net margin

Amneal Pharmaceuticals operating margin, year by year

Amneal Pharmaceuticals (AMRX) operating margin by fiscal year
Fiscal yearOperating marginChangeYear endedGross marginNet margin
202513.2% 0.7 pts up36.9%2.4%
202412.5% 2.5 pts up36.5%-4.2%
202310.0% 1.4 pts up34.3%-3.5%
20228.5% 1.2 pts up35.5%-5.9%
20217.3% 2.7 pts up36.7%0.6%
20204.6% 19.9 pts up31.5%3.4%
2019-15.3% 14.1 pts down21.7%-37.1%
2018-1.2% 24.9 pts down43.1%-1.2%
201723.7% 4.3 pts down50.9%0.0%
201628.0%—58.7%0.0%

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

Operating margin at health care companies of similar size

Operating margin of Amneal Pharmaceuticals and comparable companies
CompanyOperating marginFiscal year
Cytokinetics CYTK-695.4%2025
Bausch + Lomb BLCO3.7%2025
Amneal Pharmaceuticals AMRX13.2%2025
Caris Life Sciences CAI5.6%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AMRX

Amneal Pharmaceuticals, figure by figure

Amneal Pharmaceuticals (AMRX) overview: price, valuation and scorecardAll health care companies by market value

Amneal Pharmaceuticals operating margin: questions and answers

What is Amneal Pharmaceuticals's operating margin?

Amneal Pharmaceuticals (AMRX) had an operating margin of 13.2% in fiscal 2025 (the year ended December 31, 2025). That is 0.7 percentage points higher than the 12.5% of fiscal 2024.

Is Amneal Pharmaceuticals's operating margin high or low compared with its own history?

The fiscal 2025 figure is higher than in 78% of the 9 earlier fiscal years on record, whose median is 8.5%.

What are the highest and lowest operating margin figures on record for Amneal Pharmaceuticals?

Across the 10 fiscal years on record (2016–2025), the highest was 28.0% in fiscal 2016 and the lowest -15.3% in fiscal 2019.

What are Amneal Pharmaceuticals's gross and net margins?

Gross margin was 36.9% in fiscal 2025. Net margin was 2.4% in fiscal 2025.

How is Amneal Pharmaceuticals's operating margin calculated?

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Amneal Pharmaceuticals (AMRX) operating margin”, data as of 18 November 2026. https://funkfolio.com/stock/AMRX/operating-margin

Underlying data: the company's filings with the SEC and Yahoo Finance.